Literature DB >> 3124293

Protective effect of ICRF-187 on doxorubicin-induced cardiac and renal toxicity in spontaneously hypertensive (SHR) and normotensive (WKY) rats.

E H Herman1, A el-Hage, V J Ferrans.   

Abstract

Loss of body weight, cardiomyopathy, and nephropathy were the main toxic manifestations found when male spontaneously hypertensive rats (SHR) and genetically related Wistar-Kyoto (WKY) rats were given 1 mg/kg doxorubicin iv once a week for 12 weeks. Each of these alterations was more severe in SHR. The most profound effects on body weight were observed from the 7th to the 12th week of dosing. During this period the body weight of SHR declined to preinjection control levels. Weight loss also occurred in WKY given doxorubicin, but was not as profound. Pretreatment with 25 mg/kg ICRF-187 ip attenuated the doxorubicin-induced loss in body weight in both types of animals. The frequency and severity of cardiac and renal lesions were graded on a score of 0 to 4. Alterations were found in hearts of all SHR and four of five WKY given doxorubicin alone. Cytoplasmic vacuolization and myofibrillar loss were more severe in SHR (average score, 2.6) than in WKY (average score, 1.0). At the end of the study mean arterial pressure was also decreased in SHR which had received doxorubicin alone. Pretreatment with ICRF-187 significantly attenuated the severity of the lesions in both SHR (average score, 1.0) and WKY (average score, 0); mean arterial pressure was higher in SHR treated with ICRF-187 and doxorubicin than in saline-treated SHR. Renal alterations, including glomerular vacuolization and tubular dilatation, were found in both strains of rats (average scores, 4.0 in SHR and 3.0 in WKY). ICRF-187 also reduced the severity of renal lesions (average scores, 2.0 in SHR and 1.0 in WKY). Thus, although ICRF-187 significantly alters myocardial, renal, and body weight effects of doxorubicin in both strains of rats, these toxic effects are more severe in SHR than in WKY. SHR provide an useful animal model for the critical examination of agents with potential protective activity against doxorubicin-induced toxicity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3124293     DOI: 10.1016/0041-008x(88)90226-8

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  16 in total

1.  The influence of lipoic acid on adriamycin induced nephrotoxicity in rats.

Authors:  Kumaravel Palanichamy Malarkodi; Andithangal Venkatesan Balachandar; Palaninathan Varalakshmi
Journal:  Mol Cell Biochem       Date:  2003-05       Impact factor: 3.396

2.  Protective effect of lipoic acid on adriamycin induced lipid peroxidation in rat kidney.

Authors:  Kumaravel Palanichamy Malarkodi; Andithangal Venkatesan Balachandar; Palaninathan Varalakshmi
Journal:  Mol Cell Biochem       Date:  2003-05       Impact factor: 3.396

3.  The influence of lipoic acid on adriamycin-induced hyperlipidemic nephrotoxicity in rats.

Authors:  Kumaravel Palanichamy Malarkodi; Andithangal Venkatesan Balachandar; Palaninathan Varlakshmi
Journal:  Mol Cell Biochem       Date:  2003-05       Impact factor: 3.396

Review 4.  Iron chelators with topoisomerase-inhibitory activity and their anticancer applications.

Authors:  V Ashutosh Rao
Journal:  Antioxid Redox Signal       Date:  2012-10-26       Impact factor: 8.401

Review 5.  The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review.

Authors:  S M Swain; P Vici
Journal:  J Cancer Res Clin Oncol       Date:  2003-10-17       Impact factor: 4.553

6.  Timing of treatment with ICRF-187 and its effect on chronic doxorubicin cardiotoxicity.

Authors:  E H Herman; V J Ferrans
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Prevention of doxorubicin-induced myocardial and haematological toxicities in rats by the iron chelator desferrioxamine.

Authors:  M M al-Harbi; N M al-Gharably; O A al-Shabanah; A M al-Bekairi; A M Osman; H N Tawfik
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  Effects of ICRF-187 on the cardiac and renal toxicity of epirubicin in spontaneously hypertensive rats.

Authors:  M Dardir; E H Herman; V J Ferrans
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

9.  Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats.

Authors:  E H Herman; J Zhang; V J Ferrans
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

10.  The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-fluorouracil, and tamoxifen in metastatic breast-cancer patients.

Authors:  P Jakobsen; B Sørensen; L Bastholt; M R Mirza; S B Gjedde; H T Mouridsen; C Rose
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.